Central German Study for Immunotherapy in Thoracic Surgery

Central German Study for Immunotherapy in Thoracic Surgery - MITT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037956

Enrollment

200

Registered

2025-09-26

Start date

2025-08-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Patients who underwent surgery following neoadjuvant immunochemotherapy and surgery for NSCLC

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Preoperative immunotherapy prior to resection of NSCLC Surgery after 31 December 2022

Exclusion criteria

Exclusion criteria: Patients without prior neoadjuvant treatment with an immune checkpoint inhibitor in their personal medical history Surgery for palliative purposes (e.g. debulking, tumour haemorrhage, etc.)

Design outcomes

Primary

Measure	Time frame
Surgical outcome - R0 resection rate - Conversion rate (minimally invasive to open surgery) - 90-day morbidity and mortality (Clavian-Dindo classification) - Remission (according to RECIST) and response (according to Junker et al.)	—

Secondary

Measure	Time frame
Overall survival (OS) Recurrence-free survival (RFS)	—

Countries

Germany

Contacts

Public ContactNiels Dörr-Jerat

Klinik für Thoraxchirurgie, Krankenhause Martha-Maria Halle-Dölau

niels.doerr-jerat@martha-maria.de+493455591882

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026